Brief: Sarepta Therapeutics Set To Join S&P Midcap 400
29/05/2024 23:20
Johnson & Johnson JNJ.N :
* SAREPTA THERAPEUTICS SET TO JOIN S&P MIDCAP 400
Source text for Eikon: ID:nPn3DGTcQa
Further company coverage: JNJ.N
Recent news on Shockwave Medical
See all newsSarepta Therapeutics gains on S&P MidCap inclusion
Brief: Sarepta Therapeutics Set To Join S&P Midcap 400
Brief: Shockwave Medical Required Waiting Period For Johnson & Johnson Merger Expired On May 20
Shockwave Medical Inc reports results for the quarter ended in January - Earnings Summary
Brief: Shockwave Medical Q1 EPS USD 1.44